Morgan Stanley’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Morgan Stanley’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40	Closed	-$109	–	7861
2023 Q2	$109	Hold	40	–	–	﹤0.01%	7489
2023 Q1	$154	Hold	40	–	–	﹤0.01%	7538
2022 Q4	$218	Hold	40	–	–	﹤0.01%	7640
2022 Q3	$0	Hold	40	–	–	﹤0.01%	8049
2022 Q2	$1K	Hold	40	–	–	﹤0.01%	7743
2022 Q1	$1K	Hold	40	–	–	﹤0.01%	7914
2021 Q4	$2K	Hold	40	–	–	﹤0.01%	7828
2021 Q3	$4K	Sell	40 -67	-63%	-$6.93K	﹤0.01%	7568
2021 Q2	$15K	Buy	107 +60	+128%	+$15K	﹤0.01%	7109
2021 Q1	$13K	Buy	+47	New	+$13.8K	﹤0.01%	6875

Morgan Stanley's KRBP Position: Q3 2023 in Review

Morgan Stanley sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q3 2023, closing a stake of 40 shares — an estimated $109 sold.

Morgan Stanley first reported a position in KRBP in Q1 2021 and held it in 10 quarters. The position peaked at $15K in Q2 2021. 0 funds tracked by Wall St. Rank hold KRBP as of Q3 2023.

Morgan Stanley reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 40 Kiromic BioPharma, Inc. Common Stock shares in Q3 2023, an estimated $109.
Morgan Stanley first reported a position in Kiromic BioPharma, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Morgan Stanley's Kiromic BioPharma, Inc. Common Stock position peaked at $15K in Q2 2021.
0 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.